Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

905 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D. Creutzig U, et al. Among authors: reinhardt d. J Clin Oncol. 2006 Sep 20;24(27):4499-506. doi: 10.1200/JCO.2006.06.5037. J Clin Oncol. 2006. PMID: 16983120 Clinical Trial.
Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bökkerink JP, Tissing WJ, Samuelsson U, Feingold J, Creutzig U, Kaspers GJ. Zwaan CM, et al. Among authors: reinhardt d. Blood. 2003 May 15;101(10):3868-71. doi: 10.1182/blood-2002-07-1947. Epub 2003 Jan 23. Blood. 2003. PMID: 12543868 Free article. Clinical Trial.
Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides.
Langer T, Metzler M, Reinhardt D, Viehmann S, Borkhardt A, Reichel M, Stanulla M, Schrappe M, Creutzig U, Ritter J, Leis T, Jacobs U, Harbott J, Beck JD, Rascher W, Repp R. Langer T, et al. Among authors: reinhardt d. Genes Chromosomes Cancer. 2003 Apr;36(4):393-401. doi: 10.1002/gcc.10167. Genes Chromosomes Cancer. 2003. PMID: 12619163
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hählen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F. Zwaan CM, et al. Among authors: reinhardt d. Blood. 2003 Oct 1;102(7):2387-94. doi: 10.1182/blood-2002-12-3627. Epub 2003 Jun 19. Blood. 2003. PMID: 12816873 Free article.
Population pharmacokinetics of liposomal daunorubicin in children.
Hempel G, Reinhardt D, Creutzig U, Boos J. Hempel G, et al. Among authors: reinhardt d. Br J Clin Pharmacol. 2003 Oct;56(4):370-7. doi: 10.1046/j.1365-2125.2003.01886.x. Br J Clin Pharmacol. 2003. PMID: 12968981 Free PMC article. Clinical Trial.
Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia.
Metzler M, Strissel PL, Strick R, Niemeyer C, Roettgers S, Borkhardt A, Harbott J, Ludwig WD, Stanulla M, Schrappe M, Reinhardt D, Creutzig U, Beck JD, Rascher W, Repp R, Langer T. Metzler M, et al. Among authors: reinhardt d. Genes Chromosomes Cancer. 2004 Nov;41(3):291-6. doi: 10.1002/gcc.20083. Genes Chromosomes Cancer. 2004. PMID: 15334554
Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U, Reinhardt D. Puhlmann U, et al. Among authors: reinhardt d. J Pharmacol Exp Ther. 2005 Jan;312(1):346-54. doi: 10.1124/jpet.104.071571. Epub 2004 Oct 22. J Pharmacol Exp Ther. 2005. PMID: 15501994
905 results